HIMS
Barclays just hit the “buy more” button
Hims & Hers got a fresh vote of confidence from Barclays, which raised its price target from $29 to $39 and kept an Overweight rating on the stock. Translation: one of Wall Street’s bigger name-checkers looked at the setup and said, “Yep, still like it.”
Why the Street is suddenly less grumpy
The catalyst here isn’t just vibes. Barclays pointed to improving signals in Hims’ GLP-1 business after the company’s partnership announcement with Novo Nordisk. The bank also flagged some pretty solid engagement stats: website traffic was up 12% year over year in April and 35% in May, while transactions rose 16% month over month and spending climbed 14% in May.
The chart nerds are probably smiling too
Shares were up nearly 10% to $35.06 when this crossed the tape, and the stock has now climbed well above its short-term moving averages. That matters because Hims has spent the last year looking like it got dumped at prom — still down big over 12 months, but now trying to stage a comeback with momentum on its side.
Big picture
For investors, the story is pretty simple: Barclays thinks Hims’ growth engine is re-accelerating, and the GLP-1 angle is doing a lot of the heavy lifting. If that demand stays hot, the stock could keep running; if not, those overhead resistance levels near the mid-$30s may start acting like a velvet rope again.